Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Cited by (1,000)

Items 601–700 of 1,000

1. Improving physicochemical properties of Ibrutinib with cocrystal strategy based on structures and natures of the carboxylic acid co-formers
   Xiangjun Shi, Chao Wang, Qifeng Chen, Shuimei Shen, Shengjie Song, Xiyue Zhou · 2021 · Journal of Drug Delivery Science and Technology
2. High-risk MCL: recognition and treatment
   Preetesh Jain, Michael L. Wang · 2024 · Blood
3. Novel agents for relapsed and refractory follicular lymphoma
   Chan Yoon Cheah, Nathan Hale Fowler · 2017 · Best Practice & Research Clinical Haematology
4. Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment
   Akriti Gupta Jain, Chung-Che Chang, Sarfraz Ahmad, Shahram Mori · 2019 · Current Treatment Options in Oncology
5. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
   David Alan Bond, Peter Martin, Kami J. Maddocks · 2021 · Journal of Clinical Medicine
6. CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
   Yuki Kagiyama, Shuhei Fujita, Yutaka Shima, Kazutsune Yamagata, Takuo Katsumoto, Makoto Nakagawa, Daisuke Honma, Nobuaki Adachi, Kazushi Araki, Ayako Kato et al. · 2021 · Cancer Science
7. The Comprehensive Cancer Center
   Aljurf, Mahmoud, Navneet S. Majhail, Mickey Koh, Kharfan-Dabaja, Mohamed A., Nelson Jen An Chao · 2021 · Springer eBooks
8. Zanubrutinib in lymphoproliferative disorders: a comprehensive review
   Javier L Munoz, Yucai Wang, Preetesh Jain, Michael L. Wang · 2022 · Therapeutic Advances in Hematology
9. Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives
   Debasis Das, Jingbing Wang, Jian Hong · 2022 · Current Topics in Medicinal Chemistry
10. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
    Steven Le Gouill, Monika Długosz‐Danecka, Simon A. Rule, Pier Luigi Zinzani, Andre Henri Goy, Stephen Douglas Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal Dinesh Shah, Andrew John Davies et al. · 2023 · Haematologica
11. Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors
    Daojun Zhu, Shruti Bhatt, X Lu, F Guo, Hendrik Veelken, Daniel K. Hsu, F‐T Liu, S Alvarez Cubela, Kranthi Kunkalla, Francisco Vega et al. · 2015 · Leukemia
12. Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades
    Vijaya Raj Bhatt, Fausto R. Loberiza, Hongmei Jing, R. Gregory Bociek, Philip Jay Bierman, Lori J. Maness, Julie Marie Vose, James Olen Armitage, Mojtaba Akhtari · 2015 · Clinical Lymphoma Myeloma & Leukemia
13. Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies
    James Anthony Torchia, Kipp Weiskopf, Ronald Levy · 2016 · Proceedings of the National Academy of Sciences
14. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
    Francesco F. Zaja, Simone Ferrero, Caterina Cecilia Stelitano, Angela Ferrari, Flavia Salvi, Annalisa Arcari, Gerardo Musuraca, Barbara Botto, Michele Spina, Claudia Cellini et al. · 2017 · Haematologica
15. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers
    Thomas Hueso, Thomas Gastinne, Sylvain Garciaz, Emmanuelle Tchernonog, Caroline Delette, Olivier Casasnovas, Éric Durot, Roch Houot, Benoît Tessoulin, Olivier Tournilhac et al. · 2020 · Bone Marrow Transplantation
16. Nephrotoxic Chemotherapy Agents: Old and New
    Anthony Nicolaysen · 2020 · Advances in Chronic Kidney Disease
17. Ibrutinib in B-cell lymphoma: single fighter might be enough?
    Chao Xue, Xin Wang, Lingyan Zhang, Qingyuan Qu, Qian Zhang, Yujie Jiang · 2020 · Cancer Cell International
18. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
    Simon A. Rule, David L. Tucker · 2015 · Therapeutics and Clinical Risk Management
19. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
    Riccardo Bomben, Simone Ferrero, Tiziana D’Agaro, Michele Dal Bo, Alessandro Re, Andrea Evangelista, Angelo Michele Carella, Alberto Zamò, Umberto Vitolo, Paola Omedè et al. · 2018 · Haematologica
20. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
    Mohamed A. Kharfan‐Dabaja, William G. Wierda, Laurence J.N. Cooper · 2013 · Leukemia
21. Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superiorin vivoefficacy compared to ONO/GS-4059 in combination with rituximab
    Tomoko Yasuhiro, Wako Sawada, Christian Klein, Ryohei Kozaki, Shingo Hotta, Toshio Yoshizawa · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
22. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma
    Claire Telford, Shaum Kabadi, Sarang S. Abhyankar, Jinlin Song, James Signorovitch, Jing Zhao, Zhiwen Yao · 2019 · Clinical Therapeutics
23. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function
    January M. Watters, Gabriela M. Wright, Matthew A. Smith, Bijal Dinesh Shah, Kenneth L. Wright · 2020 · Biochemical and Biophysical Research Communications
24. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
    Xiaohong Zhao, Michelle Y. Wang, Huijuan Jiang, Tint Lwin, Paul M.C. Park, Jing Gao, Mark B. Meads, Yuan Ren, Tao Li, Jiao Sun et al. · 2021 · Cell Reports
25. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
    Graham P. Collins, Toby Andrew Eyre, Debora Schmitz-Rohmer, William M. Townsend, Rakesh Popat, Lisa G. Giulino-Roth, Paul A. Fields, Fatime Krasniqi, Carole Soussain, Anastasios Stathis et al. · 2021 · HemaSphere
26. Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
    Xin Yu, Wenhao Guo, Hanfeng Lin, Ran Cheng, Erika Y. Monroy, Feng Jin, Lang Ding, Dong Lu, Xiaoli Qi, Meng Carla Wang et al. · 2022 · Current Research in Chemical Biology
27. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
    Khalil Saleh, Morgane Cheminant, David Chiron, Barbara Burroni, Vincent Ribrag, Clémentine Sarkozy · 2022 · Cancers
28. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja et al. · 2023 · Blood Cancer Journal
29. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
    Salomé Decombis, Céline Bellanger, Yannick Le Bris, Candice Madiot, Jane Jardine, Juliana Carvalho Santos, Delphine Boulet, Christelle Dousset, Audrey Ménard, Charlotte Kervoëlen et al. · 2023 · Blood
30. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
    Wing Keung Chan, Jessica Lynn Williams, Kinnari Sorathia, Betsy A. Pray, Kaled Abusaleh, Zehua Bian, Archisha Sharma, Ian Hout, Shamama Nishat, Walter G. Hanel et al. · 2023 · Experimental Hematology and Oncology
31. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor
    Qianmao Liang, Yongfei Chen, Kailin Yu, Cheng Chen, Shouxiang Zhang, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang et al. · 2017 · European Journal of Medicinal Chemistry
32. Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
    Irene Yu-Shing Chong, Lauren I. Aronson, Hanna Bryant, Aditi Gulati, James Campbell, Richard J. R. Elliott, Stephen J. Pettitt, Paul M Wilkerson, Maryou B.K. Lambros, Jorge Sergio Reis-Filho et al. · 2017 · Gut
33. Mature lymphoid malignancies: origin, stem cells, and chronicity
    Simon Husby, Kirsten Grønbæk · 2017 · Blood Advances
34. MARCKS regulates tonic and chronic active B cell receptor signaling
    Chenguang Xu, Yan Fang, Zhiyong Yang, Yukai Jing, Yonghui Zhang, Chaohong Liu, Wanli Liu · 2018 · Leukemia
35. Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
    Yaya Chu, Sanghoon Lee, Tishi Shah, Changhong Yin, Matthew John Barth, Rodney R. Miles, Janet S Ayello, Erin Morris, Lauren Harrison, Carmella van de Ven et al. · 2018 · OncoImmunology
36. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014
    Frederick R. Appelbaum, Claudio Anasetti, Joseph H. Antin, Harold L. Atkins, Stella M. Davies, Steven Michael Devine, Sergio Giralt, Helen Elisabeth Heslop, Ginna G. Laport, Stephanie Joi Lee et al. · 2014 · Transplantation and Cellular Therapy
37. Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor
    Xuejun Zhang, Xijun Sheng, Jie Shen, Shoubo Zhang, Wenjie Sun, Chunli Shen, Yi Li, Jun Wang, Huqiang Lv, Minghui Cui et al. · 2019 · ACS Medicinal Chemistry Letters
38. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
    Ying C. Ou, Zhiyu Tang, William F. Novotny, Manal Tawashi, Ta-Kai Li, H. Coleman, Srikumar Sahasranaman · 2020 · British Journal of Clinical Pharmacology
39. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
    Caitlin M. Stewart, Laure Michaud, Karissa A. Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Matthew J. Matasar, John F. Gerecitano, Pamela R. Drullinsky et al. · 2021 · Clinical Cancer Research
40. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma
    Cristina López, Elisabeth Silkenstedt, Martin H. Dreyling, Sı́lvia Beà · 2024 · Blood Advances
41. Cryptococcosis Associated With Biologic Therapy: A Narrative Review
    Xin Li, Olivier Paccoud, K.H. Chan, Kwok‐Yung Yuen, Romain Manchon, Fanny Lanternier, Monica A. Slavin, Frank L. van de Veerdonk, Tihana A. Bicanic, Olivier Lortholary · 2024 · Open Forum Infectious Diseases
42. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update
    Robert Jr. Roskoski · 2025 · Pharmacological Research
43. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice
    Irit Mazza Avivi, Andre Henri Goy · 2015 · Clinical Cancer Research
44. Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support
    Karen P. Seiter, Michael Stiefel, Jacqueline C. Barrientos, Azfar Uddin Shaikh, Nasir Uddin Ahmed, Paul Baskind, Delong Liu · 2016 · Stem Cell Investigation
45. Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
    Gilad Itchaki, Jennifer R. Brown · 2017 · Therapeutic Advances in Hematology
46. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
    Jeffrey Wang, Jacqueline Wang, Elyse Lopez, Hui Guo, Hui Zhang, Yang Liu, Zhihong Chen, Shengjian Huang, Shouhao Zhou, Angela Leeming et al. · 2019 · Blood Cancer Journal
47. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
    Ann Tivey, Rohan Shotton, Toby Andrew Eyre, David John Lewis, Louise Stanton, Rebecca Allchin, Harriet S. Walter, Fiona M. Miall, Rui Zhao, Anna Santarsieri et al. · 2023 · Blood Advances
48. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia
    Gabriel N. Mannis, Davina Wu, Tiffany Dea, Theodora M. Mauro, Gerald Hsu · 2014 · American Journal of Hematology
49. The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
    Valkal Bhatt, Linh Alejandro, Angela Michael, Alex Ganetsky · 2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
50. Mantle cell lymphoma: observation to transplantation
    Babak Rajabi, John William Sweetenham · 2014 · Therapeutic Advances in Hematology
51. Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: A Systematic Review
    Mohamed A. Kharfan‐Dabaja, Tea Reljic, Jessica El‐Asmar, Taiga Nishihori, Ernesto Ayala, Mehdi Hamadani, Ambuj Kumar · 2016 · Future Oncology
52. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab
    Matthew Genyeh Mei, Thai M. Cao, Lu Chen, Joo Young Song, Tanya Siddiqi, Ji‐Lian Cai, Leonardo T. Farol, Monzr M. Al Malki, Amandeep Salhotra, Ibrahim Taha Aldoss et al. · 2017 · Transplantation and Cellular Therapy
53. Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All
    Bijal Dinesh Shah, Xiaohong Zhao, Ariosto Siqueira Silva, Kenneth H. Shain, Jianguo Tao · 2018 · Trends in cancer
54. Ibrutinib in CLL/SLL: From bench to bedside (Review)
    Fuming Zi, Yu Li, Qingzhi Shi, Aiping Tang, Jing Cheng · 2019 · Oncology Reports
55. Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review
    Jenica N. Upshaw · 2020 · Current Oncology Reports
56. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
    Brendan Paul Hodkinson, Michael Schäffer, Joshua Brody, Wojciech J. Jurczak, Cecilia del Carmen Carpio, Dina Ben‐Yehuda, Irit Mazza Avivi, Ann Forslund, Muhıt Özcan, John David Alvarez et al. · 2020 · Translational Oncology
57. Axicabtagene Ciloleucel and Brexucabtagene Autoleucel in Relapsed and Refractory Diffuse Large B-Cell and Mantle Cell Lymphomas
    Patrick Michael Reagan, Jonathan W. Friedberg · 2021 · Future Oncology
58. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis
    Alexandros Rampotas, Matthew R. Wilson, Oliver Lomas, Nicholas Denny, Heather Leary, Graeme Ferguson, Pam McKay, Tim Ebsworth, Jonathan L Miller, Nimish Shah et al. · 2021 · British Journal of Haematology
59. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*
    Jan de Jong, Donna M. Skee, Peter Hellemans, James Juhui Jiao, Ronald de Vries, Dominique Swerts, Eric Lawitz, Thomas C Marbury, William Smith, Juthamas Sukbuntherng et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
60. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
    Greg Coffey, Aradhana Rani, Andreas Betz, Yvonne Pak, Helena Haberstock-Debic, Anjali Pandey, Stanley J. Hollenbach, Daniel D. Gretler, Tim Mant, Stipo Jurčević et al. · 2016 · The Journal of Clinical Pharmacology
61. Electrophysiologic Toxicity of Chemoradiation
    Merna A. Armanious, Shreya V. Mishra, Michael G. Fradley · 2018 · Current Oncology Reports
62. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
    David Alan Bond, Kami J. Maddocks · 2020 · Hematology/Oncology Clinics of North America
63. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
    Sarah E. Nocco, Tyler M. Andriano, Arpita Bose, Marina Chilov, Kendra Godwin, George Dranitsaris, Shenhong Wu, Mario E. Lacouture, Lindsay E. Roeker, Anthony R. Mato et al. · 2022 · Critical Reviews in Oncology/Hematology
64. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition
    Alan B Cooper, Sravya Tumuluru, Kyle Kissick, Girish Venkataraman, Joo Young Song, Andrew G. Lytle, Gerben Duns, Jovian Yu, Nikita Kotlov, Alexander Bagaev et al. · 2023 · Journal of Clinical Oncology
65. Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study
    Emanuele Cencini, Natale Calomino, Marta Franceschini, Andreea Dragomir, Sara Fredducci, Beatrice Esposito Vangone, Giulia Lucco Navei, Alberto Fabbri, Monica Bocchia · 2024 · Hematology Reports
66. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
    Fangfang Yan, Changying Jiang, Alexa A Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yu Xue, Yijing Li, Joseph Mitchell McIntosh, Zhihong Chen et al. · 2024 · Experimental Hematology and Oncology
67. The Evolving Role of Bruton’s Tyrosine Kinase Inhibitors in B Cell Lymphomas
    Shefali Mehra, Miah Nicholls, Justin Taylor · 2024 · International Journal of Molecular Sciences
68. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia
    Song‐Yau Wang, Thomas Ebert, Nadja Jaekel, Stefan Schubert, Dietger W. Niederwieser, Haifa Kathrin Al‐Ali · 2015 · Annals of Hematology
69. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occurin vitroandin vivoand proceed through multiple mechanisms
    Tri Nguyen, Rebecca E. Parker, Elisa Hawkins, Beata Holkova, Victor Youssef Yazbeck, Akhil Kolluri, Maciej Kmieciak, Mohamed Rahmani, Steven Grant · 2017 · Oncotarget
70. Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstrom’s macroglobulinemia and review of the literature
    Anders Bisgaard Jensen, Birgitte Stausbøl‐Grøn, Rikke Riber‐Hansen, Francesco d’Amore · 2017 · Dermatology Reports
71. MYC protein dysregulation is driven by BCR ‐ PI 3K signalling in diffuse large B‐cell lymphoma
    Weige Wang, Ze‐Bing Liu, Xiang‐Nan Jiang, Jimmy Lee, Xiaoyan Zhou, Xiaoqiu Li · 2017 · Histopathology
72. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment
    Antonin Papin, Steven Le Gouill, David Chiron · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
73. Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas
    Andreas Agathangelidis, Fotis E Psomopoulos, Κώστας Σταματόπουλος · 2019 · Methods in molecular biology
74. Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma
    Matthew Stephen Ning, Chelsea Camille Pinnix, Bhavana V. Chapman, Jillian Rebecca Gunther, Sarah A. Milgrom, Joseph David Khoury, Preetesh Jain, Wendy Y. Chen, Onyeka Oriabure, Maria Badillo et al. · 2019 · Blood Advances
75. A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies
    Fu Gui, Jie Jiang, Zhixiang He, Li Li, Yunzhan Li, Zhou Deng, Yue Lu, Xinrui Wu, Guyue Chen, Jingyi Su et al. · 2019 · British Journal of Pharmacology
76. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States
    RK Goyal, Saurabh P. Nagar, Shaum Kabadi, James A. Kaye, Brian S. Seal, Anthony R. Mato · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
77. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma
    Jin‐Hua Liang, Wei‐Ting Wang, Rong Wang, Rui Gao, Kai‐Xin Du, Zi‐Wen Duan, Xinyu Zhang, Yue Li, Jia‐Zhu Wu, Hua Yin et al. · 2024 · Cancer Letters
78. Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
    Natalie Sophia Grover, Steven I. Park · 2015 · Pharmaceuticals
79. Ibrutinib and Indolent B-Cell Lymphomas
    Akintunde Akinleye, Muhammad Furqan, Oluwaseyi Adekunle · 2013 · Clinical Lymphoma Myeloma & Leukemia
80. MYC Protein–positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway
    Wei-Ge Wang, Xiang-Nan Jiang, Ze‐Bing Liu, Xiao-Yan Zhou, Xiaoqiu Li · 2017 · The American Journal of Surgical Pathology
81. Targeting CDK4/6 in mantle cell lymphoma
    Christina Y. Lee, Xiangao Huang, Maurizio Di Liberto, Peter Martin, Selina Chen‐Kiang · 2020 · Annals of Lymphoma
82. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib
    Juan Carlo Avalon, Jacob Lane Fuqua, Tyler C. Miller, Seth J. Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Michael Bianco, Lauren Westfall Veltri, Wei Fang et al. · 2021 · Cardio-Oncology
83. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
    Tycel Jovelle Phillips, David Alan Bond, Radihka Takiar, Karson J. Kump, Malathi Kandarpa, Philip S. Boonstra, Tera Mayer, Victoria R. Nachar, Ryan A. Wilcox, Shannon A. Carty et al. · 2023 · Blood Advances
84. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
    Arnau Montraveta, Sílvia Xargay‐Torrent, Mònica López‐Guerra, Laia Rosich, Patricia Pérez‐Galán, Itziar Salaverría, Sı́lvia Beà, Susana Graciela Kalko, Mercè de Frías, Clara Campàs et al. · 2014 · Oncotarget
85. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
    Ning Ding, Xitao Li, Yunfei Shi, Lingyan Ping, Lina Wu, Kai Fu, Lixia Feng, Xiaohui Zheng, Yuqin Song, Zhengying Pan et al. · 2015 · Oncotarget
86. Specialty pharmacy for hematologic malignancies
    Susan Fajardo, Felicia Zook, Emily K. Dotson · 2016 · American Journal of Health-System Pharmacy
87. Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines
    Suchismita Mohanty, Atish Ranjan Mohanty, Natalie Sandoval, Thai H. Tran, Victoria Bedell, Jun Wu, Anna Scuto, Joyce L. Murata‐Collins, Dennis D. Weisenburger, Vu N. Ngo · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
88. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
    Georg Heß, Simon A. Rule, Wojciech J. Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Dolores M. Caballero, Cristina M. Joao, Mathias Witzens‐Harig, Isabelle Bence‐Bruckler et al. · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
89. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
    Ruifang Sun, Qianqian Yu, Ken H. Young · 2018 · Chronic Diseases and Translational Medicine
90. Lenalidomide for the treatment of mantle cell lymphoma
    Fortunato Morabito, Mamdouh Skafi, Anna Grazia Recchia, Aya Kashkeesh, Musa Y. Hindiyeh, Ali Sabatleen, Lucio Morabito, Hamdi Al‐Janazreh, Yousef Hamamreh, Massimo Gentile · 2019 · Expert Opinion on Pharmacotherapy
91. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
    Barbara Kiesewetter, Nathan I. Cherny, Nicolas Boissel, Francesco Cerisoli, Urania G. Dafni, Elisabeth G.E. de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González‐Calle, Brian J.P. Huntly et al. · 2020 · ESMO Open
92. Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
    Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, Catherine Thiéblemont, Sophie de Guibert, Florian Zettl, Lawrence M. Gelbert, P. Kellie Turner, Siva Rama Prasad Kambhampati, Li Li et al. · 2020 · Haematologica
93. Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo
    Xiaominting Song, Huanan Rao, Chuanjie Guo, Bo Yang, Yali Ren, Miao Wang, Yuzhi Li, Zhixing Cao, Jin Pei · 2021 · Phytomedicine
94. Novel treatments in B cell non-Hodgkin’s lymphomas
    Yazeed Sawalha, Kami J. Maddocks · 2022 · BMJ
95. Comprehending binding features between ibrutinib and Human Alpha-1 acid glycoprotein: Combined experimental approaches and theoretical simulations
    Shao‐Liang Jiang, Li Li, Lu Hu, Song‐Bo Kou, Jie‐Hua Shi · 2022 · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy
96. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Dai Maruyama, Hirokazu Nagai, Noriko Fukuhara, Toshiyuki Kitano, Takayuki Ishikawa, Hirohiko Shibayama, Ilseung Choi, Kiyohiko Hatake, Toshiki Uchida, Momoko Nishikori et al. · 2016 · Cancer Science
97. R‐High‐ CHOP / CHASER / LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY
    Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima, Masashi Wakabayashi, Kensei Tobinai, Kiyoshi Ando, Naokuni Uike, Mitsutoshi Kurosawa, Hiroshi Gomyo, Masafumi Taniwaki et al. · 2018 · Cancer Science
98. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
    Lingzhi Li, Lei Nie, Alexa A Jordan, Qingsong Cai, Yang Liu, Yijing Li, Yuxuan Che, Jovanny Vargas, Zhihong Chen, Angela Leeming et al. · 2022 · Haematologica
99. DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
    Scott F. Huntington, Stephen J. Schuster, Wei Ding, Amber B. Koehler, Danielle M. Brander, Allison Claire Rosenthal, Jose Francisco Leis, Han Win Tun, Muhamad Alhaj Moustafa, Madiha Iqbal et al. · 2023 · American Journal of Hematology
100. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma
     Nguyet-Minh Hoang, Yunxia Liu, Paul D. Bates, Alexa R. Heaton, Angelica F. Lopez, Peng Liu, Fen Zhu, Ruoyu Chen, Apoorv Kondapelli, Xiyu Zhang et al. · 2024 · Cell Reports Medicine